Avatrombopag Maleate Patent Expiration
Avatrombopag Maleate is Used for managing thrombocytopenia in adult patients with chronic immune thrombocytopenia or chronic liver disease scheduled for a procedure. It was first introduced by Akarx Inc
Avatrombopag Maleate Patents
Given below is the list of patents protecting Avatrombopag Maleate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Doptelet | US7638536 | 2-Acylaminothiazole derivative or salt thereof | Jul 28, 2027 | Akarx Inc |
| Doptelet | US8338429 | 2-acylaminothiazole derivative or salt thereof |
Jun 30, 2023
(Expired) | Akarx Inc |
| Doptelet | US8765764 | 2-acylaminothiazole derivative or salt thereof |
Jan 15, 2023
(Expired) | Akarx Inc |
Avatrombopag Maleate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List